Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to retrospectively investigate the response to trastuzumab in breast cancer patients in terms of the potential roles of several oncogenic pathways (phosphatase and tensin homolog (PTEN) and phosphatidylinositol 3-kinase (PI3K)) in relation to HER2 status.
|
31786856 |
2020 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
PTEN loss mediates clinical cross-resistance to CDK4/6 and PI3Kα inhibitors in breast cancer.
|
31594766 |
2020 |
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The data of previous studies reporting an important role of ERβ in tamoxifen sensitivity and our findings suggest down-regulation of ERβ triggered by PTEN knockdown contributed to the decreased response of breast cancer cells to tamoxifen observed in this study.
|
31604073 |
2020 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We identified that YAP1 promotes cell growth and inhibits cell apoptosis of BC through the phosphatase and tensin homolog deleted on chromosome 10-AKT signaling pathway, and thus suggest that YAP1 might serve as a new target for inhibiting BC progression.
|
30868052 |
2019 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The exact mechanism of ATO's carcinostatic effects in breast cancer is related to downregulating PTEN/AKT pathway via promoting RhoB.
|
31011573 |
2019 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
METABIRC and TCGA breast cancer cohort mRNA expression data analysis revealed that a high expression of the anti‑angiogenesis‑associated genes, THBS2, SERPINF1 and serpin family B member 5 (SERPINB5), and of the tumor suppressor gene, PTEN, was associated with a better overall survival (OS) of breast cancer patients.
|
31059004 |
2019 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Together, our data revealed that lncRNA MAGI2-AS3 is involved in breast cancer cell progression by regulating the miR-374a-PTEN axis.
|
30883342 |
2019 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this perspective, glioblastoma U-87 MG and breast cancer MCF7 spheroids were generated to assess the therapeutic prospect of recombinant PTEN protein.
|
31290055 |
2019 |
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Further experiments showed Znhit1 affected BC through up-regulating PTEN, along with inactivation of the PI3K/Akt/mTOR pathway.
|
30928405 |
2019 |
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
It seems that PTEN status determined by protein expression may discriminate between subgroups with poor and good prognosis in premenopausal HR-positive BC patients receiving adjuvant OA.
|
30358192 |
2019 |
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
PTEN and MFN2 protein expressions were negative correlated with Vmax and positively correlated with RI in breast cancer patients.
|
31535669 |
2019 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The role of the phosphatase and tensin homolog status in predicting pathological complete response to neoadjuvant anti-HER2 therapies in HER2-positive primary breast cancer: A meta-analysis.
|
30702584 |
2019 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The most important cause of developing hereditary breast cancer is germline mutations occurring in breast cancer (BCs) susceptibility genes, for example, BRCA1, BRCA2, TP53, CHEK2, PTEN, ATM, and PPM1D.
|
30552672 |
2019 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Downregulation of microRNA-1469 promotes the development of breast cancer via targeting HOXA1 and activating PTEN/PI3K/AKT and Wnt/β-catenin pathways.
|
30320894 |
2019 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
However, the role of PTEN alterations in north Indian breast cancer
|
30678449 |
2019 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
This study demonstrates that PUF60 is highly expressed in breast cancer; upregulation of PUF60 accelerates the progression of breast cancer through PTEN inhibition.
|
30697074 |
2019 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Transgelin 2 Promotes Paclitaxel Resistance, Migration, and Invasion of Breast Cancer by Directly Interacting with PTEN and Activating PI3K/Akt/GSK-3β Pathway.
|
31488699 |
2019 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Germline DNA from 1054 BRCA-mutation-negative Hispanic women with hereditary BC (BC diagnosed at age <51 years, bilateral BC, breast and ovarian cancer, or BC diagnosed at ages 51-70 years with ≥2 first-degree or second-degree relatives who had BC diagnosed at age <70 years), 312 local controls, and 887 multiethnic cohort controls was sequenced and analyzed for 12 known and suspected, high-penetrance and moderate-penetrance cancer susceptibility genes (ataxia telangiectasia mutated [ATM], breast cancer 1 interacting protein C-terminal helicase 1 [BRIP1], cadherin 1 [CDH1], checkpoint kinase 2 [CHEK2], nibrin [NBN], neurofibromatosis type 1 [NF1], partner and localizer of BRCA2 [PALB2], phosphatase and tensin homolog [PTEN], RAD51 paralog 3 [RAD51C], RAD51D, serine/threonine kinase 11 [STK11], and TP53).
|
31206626 |
2019 |
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
By contrast, silencing SALL2 induced downregulation of ERα and PTEN and activated the Akt/mTOR signaling, resulting in estrogen-independent growth and tamoxifen resistance in ERα-positive breast cancer.
|
31657150 |
2019 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Depleting Cdh1 accelerates breast cancer cell proliferation and cooperates with PTEN loss to promote breast tumor progression in mice.
|
31420536 |
2019 |
Breast Carcinoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Opposite Prognostic Impact of Single PTEN-loss and <i>PIK3CA</i> Mutations in Early High-risk Breast Cancer.
|
31018950 |
2019 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We analyzed PTENP1 and PTEN levels in clinical BC samples and cell lines, and found that PTENP1 and PTEN were confirmed and closely correlated with the malignancy of BC cell lines and poor clinical prognosis.
|
31196157 |
2019 |
Breast Carcinoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In addition, the interaction of exogenous RILPL2 with TUBB3 resulted in the downregulation of BC cell proliferation and migration and upregulation of PTEN expression by promoting destabilization of TUBB3.
|
31497344 |
2019 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Correction: Trail Resistance Induces Epithelial-Mesenchymal Transition and Enhances Invasiveness by Suppressing PTEN via miR-221 in Breast Cancer.
|
30897152 |
2019 |
Breast Carcinoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In the current experimental study, we scrutinized the chemoprotective effect of astraxanthin against the 7,12-dimethylbenz(a)anthracene (DMBA)-induced breast cancer via Nrf-2-Keap1 and NF-kB and mTOR/Maf-1/PTEN pathway.
|
31556759 |
2019 |